Loading…

Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury

Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n...

Full description

Saved in:
Bibliographic Details
Published in:Neurobiology of aging 2024-09, Vol.141, p.121-128
Main Authors: van Amerongen, Suzan, Das, Shreyasee, Kamps, Suzie, Goossens, Julie, Bongers, Bram, Pijnenburg, Yolande A.L., Vanmechelen, Eugeen, Vijverberg, Everard G.B., Teunissen, Charlotte E., Verberk, Inge M.W.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093
container_end_page 128
container_issue
container_start_page 121
container_title Neurobiology of aging
container_volume 141
creator van Amerongen, Suzan
Das, Shreyasee
Kamps, Suzie
Goossens, Julie
Bongers, Bram
Pijnenburg, Yolande A.L.
Vanmechelen, Eugeen
Vijverberg, Everard G.B.
Teunissen, Charlotte E.
Verberk, Inge M.W.
description Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI >5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD. •History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.
doi_str_mv 10.1016/j.neurobiolaging.2024.06.001
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3071282278</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197458024001192</els_id><sourcerecordid>3071282278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093</originalsourceid><addsrcrecordid>eNqNkb-O1DAQxi0E4paDV0AuKGgSxk5iJxLNacUB0kk0UFuOPdmdkD-LndxpqSh5BV6PJ8HLHkh0VDPF932j-X2MvRCQCxDqVZ9PuIa5pXmwO5p2uQRZ5qByAPGAbURV1ZkoG_2QbUA0OiurGi7Ykxh7ANClVo_ZRVE3UEMBG_Z9iwHbMMcDTXbg3bCS5yl7tOEzhsjt5LmbdxMtdIt8CbZHt8yBMHKa-MEuhNMS-R0te341fN0jjRh-fvsRuaeINuLvBMv3FJPtyOfuFLKOyeh4G2wKoalfw_Epe9TZIeKz-3nJPl2_-bh9l918ePt-e3WTOSmVyEQtlS-VaySgbgS2DXon2lZ2ZeW1bqGs0667unFWocWi9ZUSqtIAUkloikv28px7CPOXFeNiRooOh8FOOK_RFKCFrKXUdZK-Pktd4hMDduYQKIE5GgHm1IXpzb9dmFMXBpRJXST78_tLazui_2v-Az8Jrs8CTP_eEgYTXcLp0FNIlI2f6f8u_QIFCqen</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3071282278</pqid></control><display><type>article</type><title>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</title><source>ScienceDirect Freedom Collection</source><creator>van Amerongen, Suzan ; Das, Shreyasee ; Kamps, Suzie ; Goossens, Julie ; Bongers, Bram ; Pijnenburg, Yolande A.L. ; Vanmechelen, Eugeen ; Vijverberg, Everard G.B. ; Teunissen, Charlotte E. ; Verberk, Inge M.W.</creator><creatorcontrib>van Amerongen, Suzan ; Das, Shreyasee ; Kamps, Suzie ; Goossens, Julie ; Bongers, Bram ; Pijnenburg, Yolande A.L. ; Vanmechelen, Eugeen ; Vijverberg, Everard G.B. ; Teunissen, Charlotte E. ; Verberk, Inge M.W.</creatorcontrib><description>Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI &gt;5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD. •History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.</description><identifier>ISSN: 0197-4580</identifier><identifier>ISSN: 1558-1497</identifier><identifier>EISSN: 1558-1497</identifier><identifier>DOI: 10.1016/j.neurobiolaging.2024.06.001</identifier><identifier>PMID: 38908030</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer’s disease ; Cerebrospinal fluid ; Cognitive decline ; Synaptic biomarkers ; Traumatic brain injury</subject><ispartof>Neurobiology of aging, 2024-09, Vol.141, p.121-128</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38908030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Amerongen, Suzan</creatorcontrib><creatorcontrib>Das, Shreyasee</creatorcontrib><creatorcontrib>Kamps, Suzie</creatorcontrib><creatorcontrib>Goossens, Julie</creatorcontrib><creatorcontrib>Bongers, Bram</creatorcontrib><creatorcontrib>Pijnenburg, Yolande A.L.</creatorcontrib><creatorcontrib>Vanmechelen, Eugeen</creatorcontrib><creatorcontrib>Vijverberg, Everard G.B.</creatorcontrib><creatorcontrib>Teunissen, Charlotte E.</creatorcontrib><creatorcontrib>Verberk, Inge M.W.</creatorcontrib><title>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</title><title>Neurobiology of aging</title><addtitle>Neurobiol Aging</addtitle><description>Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI &gt;5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD. •History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.</description><subject>Alzheimer’s disease</subject><subject>Cerebrospinal fluid</subject><subject>Cognitive decline</subject><subject>Synaptic biomarkers</subject><subject>Traumatic brain injury</subject><issn>0197-4580</issn><issn>1558-1497</issn><issn>1558-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkb-O1DAQxi0E4paDV0AuKGgSxk5iJxLNacUB0kk0UFuOPdmdkD-LndxpqSh5BV6PJ8HLHkh0VDPF932j-X2MvRCQCxDqVZ9PuIa5pXmwO5p2uQRZ5qByAPGAbURV1ZkoG_2QbUA0OiurGi7Ykxh7ANClVo_ZRVE3UEMBG_Z9iwHbMMcDTXbg3bCS5yl7tOEzhsjt5LmbdxMtdIt8CbZHt8yBMHKa-MEuhNMS-R0te341fN0jjRh-fvsRuaeINuLvBMv3FJPtyOfuFLKOyeh4G2wKoalfw_Epe9TZIeKz-3nJPl2_-bh9l918ePt-e3WTOSmVyEQtlS-VaySgbgS2DXon2lZ2ZeW1bqGs0667unFWocWi9ZUSqtIAUkloikv28px7CPOXFeNiRooOh8FOOK_RFKCFrKXUdZK-Pktd4hMDduYQKIE5GgHm1IXpzb9dmFMXBpRJXST78_tLazui_2v-Az8Jrs8CTP_eEgYTXcLp0FNIlI2f6f8u_QIFCqen</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>van Amerongen, Suzan</creator><creator>Das, Shreyasee</creator><creator>Kamps, Suzie</creator><creator>Goossens, Julie</creator><creator>Bongers, Bram</creator><creator>Pijnenburg, Yolande A.L.</creator><creator>Vanmechelen, Eugeen</creator><creator>Vijverberg, Everard G.B.</creator><creator>Teunissen, Charlotte E.</creator><creator>Verberk, Inge M.W.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240901</creationdate><title>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</title><author>van Amerongen, Suzan ; Das, Shreyasee ; Kamps, Suzie ; Goossens, Julie ; Bongers, Bram ; Pijnenburg, Yolande A.L. ; Vanmechelen, Eugeen ; Vijverberg, Everard G.B. ; Teunissen, Charlotte E. ; Verberk, Inge M.W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer’s disease</topic><topic>Cerebrospinal fluid</topic><topic>Cognitive decline</topic><topic>Synaptic biomarkers</topic><topic>Traumatic brain injury</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Amerongen, Suzan</creatorcontrib><creatorcontrib>Das, Shreyasee</creatorcontrib><creatorcontrib>Kamps, Suzie</creatorcontrib><creatorcontrib>Goossens, Julie</creatorcontrib><creatorcontrib>Bongers, Bram</creatorcontrib><creatorcontrib>Pijnenburg, Yolande A.L.</creatorcontrib><creatorcontrib>Vanmechelen, Eugeen</creatorcontrib><creatorcontrib>Vijverberg, Everard G.B.</creatorcontrib><creatorcontrib>Teunissen, Charlotte E.</creatorcontrib><creatorcontrib>Verberk, Inge M.W.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurobiology of aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Amerongen, Suzan</au><au>Das, Shreyasee</au><au>Kamps, Suzie</au><au>Goossens, Julie</au><au>Bongers, Bram</au><au>Pijnenburg, Yolande A.L.</au><au>Vanmechelen, Eugeen</au><au>Vijverberg, Everard G.B.</au><au>Teunissen, Charlotte E.</au><au>Verberk, Inge M.W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury</atitle><jtitle>Neurobiology of aging</jtitle><addtitle>Neurobiol Aging</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>141</volume><spage>121</spage><epage>128</epage><pages>121-128</pages><issn>0197-4580</issn><issn>1558-1497</issn><eissn>1558-1497</eissn><abstract>Traumatic brain injury (TBI) and Alzheimer’s disease (AD) have overlapping mechanisms but it remains unknown if pathophysiological characteristics and cognitive trajectories in AD patients are influenced by TBI history. Here, we studied AD patients (stage MCI or dementia) with TBI history (ADTBI+, n=110), or without (ADTBI-, n=110) and compared baseline CSF concentrations of amyloid beta 1–42 (Aβ42), phosphorylated tau181 (pTau181), total tau, neurofilament light chain (NfL), synaptosomal associated protein-25kDa (SNAP25), neurogranin (Ng), neuronal pentraxin-2 (NPTX2) and glutamate receptor-4 (GluR4), as well as differences in cognitive trajectories using linear mixed models. Explorative, analyses were repeated within stratified TBI groups by TBI characteristics (timing, severity, number). We found no differences in baseline CSF biomarker concentrations nor in cognitive trajectories between ADTBI+ and ADTBI- patients. TBI &gt;5 years ago was associated with higher NPTX2 and a tendency for higher SNAP25 concentrations compared to TBI ≤ 5 years ago, suggesting that TBI may be associated with long-term synaptic dysfunction only when occurring before onset or in a pre-clinical disease stage of AD. •History of TBI is not associated with distinct cognitive trajectories in AD.•History of remote TBI in AD may be linked to alterations in CSF synaptic biomarkers.•Independent of TBI, CSF NfL and NPTX2 are predictors for cognitive decline in AD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38908030</pmid><doi>10.1016/j.neurobiolaging.2024.06.001</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0197-4580
ispartof Neurobiology of aging, 2024-09, Vol.141, p.121-128
issn 0197-4580
1558-1497
1558-1497
language eng
recordid cdi_proquest_miscellaneous_3071282278
source ScienceDirect Freedom Collection
subjects Alzheimer’s disease
Cerebrospinal fluid
Cognitive decline
Synaptic biomarkers
Traumatic brain injury
title Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A41%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrospinal%20fluid%20biomarkers%20and%20cognitive%20trajectories%20in%20patients%20with%20Alzheimer%E2%80%99s%20disease%20and%20a%20history%20of%20traumatic%20brain%20injury&rft.jtitle=Neurobiology%20of%20aging&rft.au=van%20Amerongen,%20Suzan&rft.date=2024-09-01&rft.volume=141&rft.spage=121&rft.epage=128&rft.pages=121-128&rft.issn=0197-4580&rft.eissn=1558-1497&rft_id=info:doi/10.1016/j.neurobiolaging.2024.06.001&rft_dat=%3Cproquest_cross%3E3071282278%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2261-1826d46c920e791eb9edc1bb2f45d77b048b2f7f89ca6eae3bd56165700262093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3071282278&rft_id=info:pmid/38908030&rfr_iscdi=true